Loic Vaillant, Waseem Akhter, Jean Nakhle, Matthieu Simon, Martin Villalba, Christian Jorgensen, Marie-Luce Vignais, Javier Hernandez
{"title":"线粒体转移在间充质干细胞抑制 CD8+ T 细胞反应中的作用。","authors":"Loic Vaillant, Waseem Akhter, Jean Nakhle, Matthieu Simon, Martin Villalba, Christian Jorgensen, Marie-Luce Vignais, Javier Hernandez","doi":"10.1186/s13287-024-03980-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>. CD8<sup>+</sup> Cytotoxic T lymphocytes play a key role in the pathogenesis of autoimmune diseases and clinical conditions such as graft versus host disease and graft rejection. Mesenchymal Stromal Cells (MSCs) are multipotent cells with tissue repair and immunomodulatory capabilities. Since they are able to suppress multiple pathogenic immune responses, MSCs have been proposed as a cellular therapy for the treatment of immune-mediated diseases. However, the mechanisms underlying their immunosuppressive properties are not yet fully understood. MSCs have the remarkable ability to sense tissue injury and inflammation and respond by donating their own mitochondria to neighboring cells. Whether mitochondrial transfer has any role in the repression of CD8<sup>+</sup> responses is unknown.</p><p><strong>Methods and results: </strong>. We have utilized CD8<sup>+</sup> T cells from Clone 4 TCR transgenic mice that differentiate into effector cells upon activation in vitro and in vivo to address this question. Allogeneic bone marrow derived MSCs, co-cultured with activated Clone 4 CD8<sup>+</sup> T cells, decreased their expansion, the production of the effector cytokine IFNγ and their diabetogenic potential in vivo. Notably, we found that during this interaction leading to suppression, MSCs transferred mitochondria to CD8<sup>+</sup> T cells as evidenced by FACS and confocal microscopy. Transfer of MSC mitochondria to Clone 4 CD8<sup>+</sup> T cells also resulted in decreased expansion and production of IFNγ upon activation. These effects overlapped and were additive with those of prostaglandin E2 secreted by MSCs. Furthermore, preventing mitochondrial transfer in co-cultures diminished the ability of MSCs to inhibit IFNγ production. Finally, we demonstrated that both MSCs and MSC mitochondria downregulated T-bet and Eomes expression, key transcription factors for CTL differentiation, on activated CD8<sup>+</sup> T cells.</p><p><strong>Conclusion: </strong>. In this report we showed that MSCs are able to interact with CD8<sup>+</sup> T cells and transfer them their mitochondria. Mitochondrial transfer contributed to the global suppressive effect of MSCs on CD8<sup>+</sup> T cell activation by downregulating T-bet and Eomes expression resulting in impaired IFNγ production of activated CD8<sup>+</sup> T cells.</p>","PeriodicalId":21876,"journal":{"name":"Stem Cell Research & Therapy","volume":"15 1","pages":"394"},"PeriodicalIF":7.1000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536934/pdf/","citationCount":"0","resultStr":"{\"title\":\"The role of mitochondrial transfer in the suppression of CD8<sup>+</sup> T cell responses by Mesenchymal stem cells.\",\"authors\":\"Loic Vaillant, Waseem Akhter, Jean Nakhle, Matthieu Simon, Martin Villalba, Christian Jorgensen, Marie-Luce Vignais, Javier Hernandez\",\"doi\":\"10.1186/s13287-024-03980-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>. CD8<sup>+</sup> Cytotoxic T lymphocytes play a key role in the pathogenesis of autoimmune diseases and clinical conditions such as graft versus host disease and graft rejection. Mesenchymal Stromal Cells (MSCs) are multipotent cells with tissue repair and immunomodulatory capabilities. Since they are able to suppress multiple pathogenic immune responses, MSCs have been proposed as a cellular therapy for the treatment of immune-mediated diseases. However, the mechanisms underlying their immunosuppressive properties are not yet fully understood. MSCs have the remarkable ability to sense tissue injury and inflammation and respond by donating their own mitochondria to neighboring cells. Whether mitochondrial transfer has any role in the repression of CD8<sup>+</sup> responses is unknown.</p><p><strong>Methods and results: </strong>. We have utilized CD8<sup>+</sup> T cells from Clone 4 TCR transgenic mice that differentiate into effector cells upon activation in vitro and in vivo to address this question. Allogeneic bone marrow derived MSCs, co-cultured with activated Clone 4 CD8<sup>+</sup> T cells, decreased their expansion, the production of the effector cytokine IFNγ and their diabetogenic potential in vivo. Notably, we found that during this interaction leading to suppression, MSCs transferred mitochondria to CD8<sup>+</sup> T cells as evidenced by FACS and confocal microscopy. Transfer of MSC mitochondria to Clone 4 CD8<sup>+</sup> T cells also resulted in decreased expansion and production of IFNγ upon activation. These effects overlapped and were additive with those of prostaglandin E2 secreted by MSCs. Furthermore, preventing mitochondrial transfer in co-cultures diminished the ability of MSCs to inhibit IFNγ production. Finally, we demonstrated that both MSCs and MSC mitochondria downregulated T-bet and Eomes expression, key transcription factors for CTL differentiation, on activated CD8<sup>+</sup> T cells.</p><p><strong>Conclusion: </strong>. In this report we showed that MSCs are able to interact with CD8<sup>+</sup> T cells and transfer them their mitochondria. Mitochondrial transfer contributed to the global suppressive effect of MSCs on CD8<sup>+</sup> T cell activation by downregulating T-bet and Eomes expression resulting in impaired IFNγ production of activated CD8<sup>+</sup> T cells.</p>\",\"PeriodicalId\":21876,\"journal\":{\"name\":\"Stem Cell Research & Therapy\",\"volume\":\"15 1\",\"pages\":\"394\"},\"PeriodicalIF\":7.1000,\"publicationDate\":\"2024-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11536934/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Stem Cell Research & Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13287-024-03980-1\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL & TISSUE ENGINEERING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem Cell Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13287-024-03980-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0
摘要
背景: .CD8+ 细胞毒性 T 淋巴细胞在自身免疫性疾病和临床症状(如移植物抗宿主疾病和移植物排斥反应)的发病机制中起着关键作用。间充质基质细胞(MSCs)是一种多能细胞,具有组织修复和免疫调节功能。由于间充质干细胞能够抑制多种致病性免疫反应,因此被提议作为治疗免疫介导疾病的细胞疗法。然而,间充质干细胞的免疫抑制特性机制尚未完全明了。间充质干细胞具有感知组织损伤和炎症的卓越能力,并通过向邻近细胞捐赠自身线粒体做出反应。线粒体转移在抑制 CD8+ 反应中是否起作用尚不清楚。我们利用克隆 4 TCR 转基因小鼠的 CD8+ T 细胞在体外和体内激活后分化为效应细胞来解决这个问题。异体骨髓间充质干细胞与活化的克隆 4 CD8+ T 细胞共同培养,可减少其扩增、效应细胞因子 IFNγ 的产生及其体内致糖尿病潜能。值得注意的是,我们发现在这种导致抑制的相互作用过程中,间充质干细胞将线粒体转移到了 CD8+ T 细胞上,这一点已被 FACS 和共聚焦显微镜所证实。将间叶干细胞线粒体转移到克隆 4 CD8+ T 细胞也会导致细胞扩增和活化时 IFNγ 的产生减少。这些效应与间充质干细胞分泌的前列腺素 E2 的效应重叠并具有叠加效应。此外,在共培养过程中阻止线粒体转移会降低间充质干细胞抑制 IFNγ 生成的能力。最后,我们证实间充质干细胞和间充质干细胞线粒体都能下调活化 CD8+ T 细胞上 CTL 分化的关键转录因子 T-bet 和 Eomes 的表达。在本报告中,我们发现间充质干细胞能够与 CD8+ T 细胞相互作用,并将线粒体转移给它们。线粒体转移通过下调 T-bet 和 Eomes 的表达,导致活化的 CD8+ T 细胞产生的 IFNγ 受阻,从而促进了间充质干细胞对 CD8+ T 细胞活化的全面抑制作用。
The role of mitochondrial transfer in the suppression of CD8+ T cell responses by Mesenchymal stem cells.
Background: . CD8+ Cytotoxic T lymphocytes play a key role in the pathogenesis of autoimmune diseases and clinical conditions such as graft versus host disease and graft rejection. Mesenchymal Stromal Cells (MSCs) are multipotent cells with tissue repair and immunomodulatory capabilities. Since they are able to suppress multiple pathogenic immune responses, MSCs have been proposed as a cellular therapy for the treatment of immune-mediated diseases. However, the mechanisms underlying their immunosuppressive properties are not yet fully understood. MSCs have the remarkable ability to sense tissue injury and inflammation and respond by donating their own mitochondria to neighboring cells. Whether mitochondrial transfer has any role in the repression of CD8+ responses is unknown.
Methods and results: . We have utilized CD8+ T cells from Clone 4 TCR transgenic mice that differentiate into effector cells upon activation in vitro and in vivo to address this question. Allogeneic bone marrow derived MSCs, co-cultured with activated Clone 4 CD8+ T cells, decreased their expansion, the production of the effector cytokine IFNγ and their diabetogenic potential in vivo. Notably, we found that during this interaction leading to suppression, MSCs transferred mitochondria to CD8+ T cells as evidenced by FACS and confocal microscopy. Transfer of MSC mitochondria to Clone 4 CD8+ T cells also resulted in decreased expansion and production of IFNγ upon activation. These effects overlapped and were additive with those of prostaglandin E2 secreted by MSCs. Furthermore, preventing mitochondrial transfer in co-cultures diminished the ability of MSCs to inhibit IFNγ production. Finally, we demonstrated that both MSCs and MSC mitochondria downregulated T-bet and Eomes expression, key transcription factors for CTL differentiation, on activated CD8+ T cells.
Conclusion: . In this report we showed that MSCs are able to interact with CD8+ T cells and transfer them their mitochondria. Mitochondrial transfer contributed to the global suppressive effect of MSCs on CD8+ T cell activation by downregulating T-bet and Eomes expression resulting in impaired IFNγ production of activated CD8+ T cells.
期刊介绍:
Stem Cell Research & Therapy serves as a leading platform for translational research in stem cell therapies. This international, peer-reviewed journal publishes high-quality open-access research articles, with a focus on basic, translational, and clinical research in stem cell therapeutics and regenerative therapies. Coverage includes animal models and clinical trials. Additionally, the journal offers reviews, viewpoints, commentaries, and reports.